专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20110256137A1 PHARMACEUTICAL COMPOSITION COMPRISING A BISPECIFIC ANTIBODY FOR EPCAM 有权
标题翻译：包含EPCAM的双重抗体的药物组合物
公开(公告)号：US20110256137A1
公开(公告)日：2011-10-20
申请号：US13079453
申请日：2011-04-04
申请人： Peter Kufer , Meera Berry , Sonja Offner , Klaus Brischwein , Andreas Wolf , Tobias Raum , Birgit Kohleisen , Ulla Lenkkeri-Schutz , Patrick Bauerle
发明人： Peter Kufer , Meera Berry , Sonja Offner , Klaus Brischwein , Andreas Wolf , Tobias Raum , Birgit Kohleisen , Ulla Lenkkeri-Schutz , Patrick Bauerle
IPC分类号： A61K39/395 , C07H21/00 , A61P35/00 , C12P21/02 , C12N5/10 , C12N1/00 , C07K16/28 , C12N15/63
CPC分类号： C07K16/30 , A61K2039/505 , C07K16/2809 , C07K16/3076 , C07K2317/31 , C07K2317/622 , C07K2317/92 , C07K2319/00 , Y10S435/81 , Y10S435/975
摘要： The present invention provides a pharmaceutical composition comprising a bispecific single chain antibody construct. Said bispecific single chain antibody construct is characterized to comprise or consist of at least two domains, whereby one of said at least two domains specifically binds to human EpCAM and comprises at least one CDR-H3 region comprising the amino acid sequence NXID antigen and a second domain binds to human CD3 antigen. The invention further provides a process for the production of the pharmaceutical composition of the invention, a method for the prevention, treatment or amelioration of a tumorous disease and the use of the disclosed bispecific single chain antibody construct and corresponding means in the prevention, treatment or amelioration of a tumorous disease.
摘要翻译：本发明提供包含双特异性单链抗体构建体的药物组合物。所述双特异性单链抗体构建体的特征在于包含至少两个结构域或由至少两个结构域组成，其中所述至少两个结构域之一特异性结合人EpCAM并且包含至少一个CDR-H3区，其包含氨基酸序列NXID抗原和第二结构域结合人CD3抗原。本发明进一步提供了制备本发明的药物组合物的方法，一种预防，治疗或改善肿瘤疾病的方法，以及所公开的双特异性单链抗体构建体的用途和相应的手段，用于预防，治疗或改善肿瘤疾病

2. 发明授权

US08790645B2 Pharmaceutical composition comprising a bispecific antibody for EpCAM 有权
标题翻译：包含用于EpCAM的双特异性抗体的药物组合物
公开(公告)号：US08790645B2
公开(公告)日：2014-07-29
申请号：US13079453
申请日：2011-04-04
申请人： Peter Kufer , Meera Berry , Sonja Offner , Klaus Brischwein , Andreas Wolf , Tobias Raum , Birgit Kohleisen , Ulla Lenkkeri-Schütz , Patrick Bauerle
发明人： Peter Kufer , Meera Berry , Sonja Offner , Klaus Brischwein , Andreas Wolf , Tobias Raum , Birgit Kohleisen , Ulla Lenkkeri-Schütz , Patrick Bauerle
IPC分类号： A61K39/395 , C07K16/00 , C07K16/30 , C07K16/28
CPC分类号： C07K16/30 , A61K2039/505 , C07K16/2809 , C07K16/3076 , C07K2317/31 , C07K2317/622 , C07K2317/92 , C07K2319/00 , Y10S435/81 , Y10S435/975
摘要： The present invention provides a pharmaceutical composition comprising a bispecific single chain antibody construct. Said bispecific single chain antibody construct is characterized to comprise or consist of at least two domains, whereby one of said at least two domains specifically binds to human EpCAM and comprises at least one CDR-H3 region comprising the amino acid sequence NXID antigen and a second domain binds to human CD3 antigen. The invention further provides a process for the production of the pharmaceutical composition of the invention, a method for the prevention, treatment or amelioration of a tumorous disease and the use of the disclosed bispecific single chain antibody construct and corresponding means in the prevention, treatment or amelioration of a tumorous disease.
摘要翻译：本发明提供包含双特异性单链抗体构建体的药物组合物。所述双特异性单链抗体构建体的特征在于包含至少两个结构域或由至少两个结构域组成，其中所述至少两个结构域之一特异性结合人EpCAM并且包含至少一个CDR-H3区，其包含氨基酸序列NXID抗原和第二结构域结合人CD3抗原。本发明进一步提供了制备本发明的药物组合物的方法，一种预防，治疗或改善肿瘤疾病的方法，以及所公开的双特异性单链抗体构建体的用途和相应的手段，用于预防，治疗或改善肿瘤疾病

3. 发明授权

US08101722B2 Less immunogenic binding molecules 有权
标题翻译：较少的免疫原性结合分子
公开(公告)号：US08101722B2
公开(公告)日：2012-01-24
申请号：US10588734
申请日：2005-02-16
申请人： Peter Kufer , Ulla Lenkkeri-Schütz , Ralf Lutterbüse , Birgit Kohleisen
发明人： Peter Kufer , Ulla Lenkkeri-Schütz , Ralf Lutterbüse , Birgit Kohleisen
IPC分类号： C12P21/08
CPC分类号： C07K16/2809 , C07K16/2803 , C07K16/30 , C07K2317/31 , C07K2317/34 , C07K2317/622
摘要： The present invention provides a bispecific binding molecule, wherein said molecule comprises or consists of at least two domains whereby one of said at least two domains specifically binds to/interacts with the human CD3 complex and said domain comprises an amino acid sequence of an antibody derived light chain, wherein said amino acid sequence is a particularly identified amino acid sequence comprising specific amino acid substitutions, and a second domain is or contains at least one further antigen-interaction-site and/or at least one further effector domain. The invention further provides nucleic acid molecules encoding the bispecific binding molecules of the invention, vectors comprising said nucleic acid molecules and host cells transformed or transfected with said vectors. Moreover, the invention concerns a method for the production of bispecific binding molecules of the invention and compositions comprising the bispecific binding molecules of the invention, the nucleic acid molecules of the invention or the host cells of the invention.
摘要翻译：本发明提供双特异性结合分子，其中所述分子包含至少两个结构域或由至少两个结构域组成，其中所述至少两个结构域之一与人CD3复合物特异性结合/相互作用，并且所述结构域包含抗体衍生的氨基酸序列轻链，其中所述氨基酸序列是特别鉴定的包含特定氨基酸取代的氨基酸序列，第二结构域是或含有至少一个其它抗原相互作用位点和/或至少一个其它效应子结构域。本发明还提供了编码本发明的双特异性结合分子的核酸分子，包含所述核酸分子的载体和用所述载体转化或转染的宿主细胞。此外，本发明涉及生产本发明的双特异性结合分子的方法和包含本发明的双特异性结合分子，本发明的核酸分子或本发明的宿主细胞的组合物。

4. 发明授权

US07635472B2 Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders 有权
标题翻译：包含用于治疗b细胞相关疾病的双特异性抗cd3抗CD19抗体构建体的药物组合物
公开(公告)号：US07635472B2
公开(公告)日：2009-12-22
申请号：US10554852
申请日：2004-05-26
申请人： Peter Kufer , Ralf Lutterbuse , Birgit Kohleisen , Steven Zeman , Patrick Bauerle
发明人： Peter Kufer , Ralf Lutterbuse , Birgit Kohleisen , Steven Zeman , Patrick Bauerle
IPC分类号： A61K39/395 , C07K16/00
CPC分类号： C07K16/2803 , A61K2039/505 , C07K2317/31 , C07K2317/34 , C07K2317/622
摘要： The present invention relates to a pharmaceutical composition comprising a bispecific single chain antibody construct comprising binding domains specific for human CD3 and human CD19, wherein the corresponding variable heavy chain regions (VH) and the corresponding variable light chain regions (VL) regions are arranged, from N-terminus to C-terminus, in the order VH(CD19)-VL(CD19)-VH(CD3)-VL(CD3) or VH(CD3)-VL-(CD3)-VH(CD19)-VL (CD19). Processes for the production of the pharmaceutical compositions and medical/pharmaceutical uses for the specific bispecific single chain antibody molecules bearing specificities for the human CD3 antigen and the human CD19 antigen are also disclosed.
摘要翻译：本发明涉及包含双特异性单链抗体构建体的药物组合物，其包含对人CD3和人CD19特异性的结合结构域，其中相应的可变重链区（VH）和相应的可变轻链区（VL）区域被布置， VH（CD19）-VL（CD19）-VH（CD3）-VL（CD3）或VH（CD3）-VL-（CD3）-VH（CD19）-VL（从N末端至C末端） CD19）。还公开了用于制备针对人CD3抗原和人CD19抗原具有特异性的特异性双特异性单链抗体分子的药物组合物和医用/药物用途的方法。

5. 发明授权

US09102736B2 Multispecific deimmunized CD3-binders 有权
标题翻译：多特异性去免疫化CD3结合物
公开(公告)号：US09102736B2
公开(公告)日：2015-08-11
申请号：US13323206
申请日：2011-12-12
申请人： Robert Hofmeister , Birgit Kohleisen , Ulla Lenkkeri-Schütz , Christian Itin , Patrick Bäuerle , Francis J. Carr , Anita A. Hamilton , Stephen Williams
发明人： Robert Hofmeister , Birgit Kohleisen , Ulla Lenkkeri-Schütz , Christian Itin , Patrick Bäuerle , Francis J. Carr , Anita A. Hamilton , Stephen Williams
IPC分类号： C12P21/08 , C07K16/28 , C07K16/30 , A61K39/00
CPC分类号： C07K16/2896 , A61K2039/505 , C07K16/2803 , C07K16/2809 , C07K16/30 , C07K2317/24 , C07K2317/31 , C07K2317/567
摘要： The present invention provides a cytotoxically active CD3 specific binding construct comprising a first domain specifically binding to human CD3 and an Ig-derived second binding domain. Furthermore, a nucleic acid sequence encoding a CD3 specific binding construct of the invention is provided. Further aspects of the invention are vectors and host cells comprising said nucleic acid sequence, a process for the production of the construct of the invention and composition comprising said construct. The invention also provides the use of said constructs for the preparation of pharmaceutical compositions for the treatment of particular diseases, a method for the treatment of particular diseases and a kit comprising the binding construct of the invention.
摘要翻译：本发明提供了细胞毒活性CD3特异性结合构建体，其包含与人CD3特异性结合的第一结构域和来自Ig的第二结合结构域。此外，提供了编码本发明的CD3特异性结合构建体的核酸序列。本发明的其它方面是包含所述核酸序列的载体和宿主细胞，用于生产本发明构建体的方法和包含所述构建体的组合物。本发明还提供所述构建体用于制备用于治疗特定疾病的药物组合物，用于治疗特定疾病的方法和包含本发明的结合构建体的试剂盒的用途。

6. 发明授权

US08784821B1 Human-anti-human cd3 binding molecules 有权
标题翻译：人抗人cd3结合分子
公开(公告)号：US08784821B1
公开(公告)日：2014-07-22
申请号：US10554731
申请日：2004-05-26
申请人： Peter Kufer , Tobias Raum , Meera Berry , Roman Kischel , Susanne Mangold , Eva Krinner , Birgit Kohleisen , Steven Zeman , Christian Itin , Patrick Bäuerle
发明人： Peter Kufer , Tobias Raum , Meera Berry , Roman Kischel , Susanne Mangold , Eva Krinner , Birgit Kohleisen , Steven Zeman , Christian Itin , Patrick Bäuerle
IPC分类号： A61K38/00
CPC分类号： C07K16/24 , A61K2039/505 , C07K16/2803 , C07K16/2809 , C07K16/2896 , C07K16/30 , C07K2317/21 , C07K2317/31 , C07K2317/34
摘要： The present invention provides a method for the preparation of a human binding molecule, fragment or derivative thereof which specifically binds to the human CD3 complex. Furthermore, the invention provides a human binding molecules specifically binding to the human CD3 complex and means comprising said human binding molecules.
摘要翻译：本发明提供了制备与人CD3复合物特异性结合的人结合分子，其片段或衍生物的方法。此外，本发明提供了特异性结合人CD3复合物的人结合分子和包含所述人结合分子的手段。

7. 发明授权

US08076459B2 Multispecfic deimmunized CD3-binders 有权
标题翻译：多特异性去免疫化CD3-结合物
公开(公告)号：US08076459B2
公开(公告)日：2011-12-13
申请号：US10572740
申请日：2004-10-15
申请人： Robert Hofmeister , Birgit Kohleisen , Ulla Lenkkeri-Schütz , Christian Itin , Patrick Bäuerle , Francis J. Carr , Anita A. Hamilton , Stephen Williams
发明人： Robert Hofmeister , Birgit Kohleisen , Ulla Lenkkeri-Schütz , Christian Itin , Patrick Bäuerle , Francis J. Carr , Anita A. Hamilton , Stephen Williams
IPC分类号： C12P21/08 , C12P21/04 , C07H21/04 , C12Q1/68 , G01N33/53 , C12N15/00 , A61K39/00
CPC分类号： C07K16/2896 , A61K2039/505 , C07K16/2803 , C07K16/2809 , C07K16/30 , C07K2317/24 , C07K2317/31 , C07K2317/567
摘要： The present invention provides a cytotoxically active CD3 specific binding construct comprising a first domain specifically binding to human CD3 and an IG-derived second binding domain. Furthermore, a nucleic acid sequence encoding a CD3 specific binding construct is provided. Further aspects of the invention are vectors and host cells comprising the nucleic acid sequences, a process for the production of the construct and composition comprising the construct. The invention also provides the use of the constructs for the preparation of pharmaceutical compositions for the treatment of particular diseases, a method for the treatment of particular diseases and a kit comprising the binding construct of the invention.
摘要翻译：本发明提供细胞毒活性的CD3特异性结合构建体，其包含与人CD3特异性结合的第一结构域和来自IG的第二结合结构域。此外，提供编码CD3特异性结合构建体的核酸序列。本发明的其它方面是包含核酸序列的载体和宿主细胞，用于生产构建体的方法和包含该构建体的组合物。本发明还提供了用于制备用于治疗特定疾病的药物组合物的构建体的用途，用于治疗特定疾病的方法和包含本发明的结合构建体的试剂盒。

8. 发明申请

US20070123479A1 Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders 有权
标题翻译：包含用于治疗b细胞相关疾病的双特异性抗cd3抗CD19抗体构建体的药物组合物
公开(公告)号：US20070123479A1
公开(公告)日：2007-05-31
申请号：US10554852
申请日：2004-05-26
申请人： Peter Kufer , Ralf Lutterbuse , Birgit Kohleisen , Steven Zeman , Patrick Bauerle
发明人： Peter Kufer , Ralf Lutterbuse , Birgit Kohleisen , Steven Zeman , Patrick Bauerle
IPC分类号： A61K39/395 , A61K48/00
CPC分类号： C07K16/2803 , A61K2039/505 , C07K2317/31 , C07K2317/34 , C07K2317/622
摘要： The present invention relates to a pharmaceutical composition comprising a bispecific single chain antibody construct, said bispecific single chain antibody construct comprising binding domains specific for human CD3 and human CD19, wherein the corresponding variable heavy chain regions (VH) and the corresponding variable light chain regions (VL) regions are arranged, from N-terminus to C-terminus, in the order, VH(CD19)-VL(CD19)-VH(CD3)-VL(CD3), VH(CD3)-VL-(CD3)-VH(CD19)-VL(CD19) or VH(CD3)-VL(CD3)-VL(CD19)-VH(CD19). Furthermore, processes for the production of said pharmaceutical compositions as well as medical/pharmaceutical uses for the specific bispecific single chain antibody molecules bearing specificities for the human CD3 antigen and the human CD19 antigen are disclosed.
摘要翻译：本发明涉及包含双特异性单链抗体构建体的药物组合物，所述双特异性单链抗体构建体包含对人CD3和人CD19特异的结合结构域，其中相应的可变重链区（V H H H））和相应的可变轻链区域（V L L）区域从N末端到C末端按顺序排列，V H（CD19）-V （CD19）-V H（CD 3）-V L（CD 3），V H（CD 3） - （CD3）-V H（CD19）-VLL（CD19）或V H（H）（CD 3）-V L（CD 3）-V L（CD 19）-V H（CD 19）。此外，公开了用于生产所述药物组合物的方法以及对于人CD3抗原和人CD19抗原具有特异性的特异性双特异性单链抗体分子的医学/药物用途。

9. 发明申请

US20130224205A1 MULTISPECIFIC DEIMMUNIZED CD3-BINDERS 有权
标题翻译：多重免疫的CD3-结合蛋白
公开(公告)号：US20130224205A1
公开(公告)日：2013-08-29
申请号：US13323206
申请日：2011-12-12
申请人： Robert HOFMEISTER , Birgit Kohleisen , Ulla Lenkkeri-Schütz , Christian Itin , Patrick Bäuerle , Francis J. Carr , Anita A. Hamilton , Stephen Williams
发明人： Robert HOFMEISTER , Birgit Kohleisen , Ulla Lenkkeri-Schütz , Christian Itin , Patrick Bäuerle , Francis J. Carr , Anita A. Hamilton , Stephen Williams
IPC分类号： C07K16/28
CPC分类号： C07K16/2896 , A61K2039/505 , C07K16/2803 , C07K16/2809 , C07K16/30 , C07K2317/24 , C07K2317/31 , C07K2317/567
摘要： The present invention provides a cytotoxically active CD3 specific binding construct comprising a first domain specifically binding to human CD3 and an Ig-derived second binding domain. Furthermore, a nucleic acid sequence encoding a CD3 specific binding construct of the invention is provided. Further aspects of the invention are vectors and host cells comprising said nucleic acid sequence, a process for the production of the construct of the invention and composition comprising said construct. The invention also provides the use of said constructs for the preparation of pharmaceutical compositions for the treatment of particular diseases, a method for the treatment of particular diseases and a kit comprising the binding construct of the invention.
摘要翻译：本发明提供了细胞毒活性的CD3特异性结合构建体，其包含与人CD3特异性结合的第一结构域和来自Ig的第二结合结构域。此外，提供了编码本发明的CD3特异性结合构建体的核酸序列。本发明的其它方面是包含所述核酸序列的载体和宿主细胞，用于生产本发明构建体的方法和包含所述构建体的组合物。本发明还提供所述构建体用于制备用于治疗特定疾病的药物组合物，用于治疗特定疾病的方法和包含本发明的结合构建体的试剂盒的用途。

10. 发明授权

US07919089B2 Pharmaceutical composition comprising a bispecific antibody for EpCAM 有权
标题翻译：包含用于EpCAM的双特异性抗体的药物组合物
公开(公告)号：US07919089B2
公开(公告)日：2011-04-05
申请号：US10554851
申请日：2004-05-26
申请人： Peter Kufer , Meera Berry , Sonja Offner , Klaus Brischwein , Andreas Wolf , Tobias Raum , Birgit Kohleisen , Ulla Lenkkeri-Schutz , Patrick Baeuerle
发明人： Peter Kufer , Meera Berry , Sonja Offner , Klaus Brischwein , Andreas Wolf , Tobias Raum , Birgit Kohleisen , Ulla Lenkkeri-Schutz , Patrick Baeuerle
IPC分类号： A61K39/395 , C07K16/00 , C07K16/24
CPC分类号： C07K16/30 , A61K2039/505 , C07K16/2809 , C07K16/3076 , C07K2317/31 , C07K2317/622 , C07K2317/92 , C07K2319/00 , Y10S435/81 , Y10S435/975
摘要： The present invention provides a pharmaceutical composition comprising a bispecific single chain antibody construct. Said bispecific single chain antibody construct is characterized to comprise or consist of at least two domains, whereby one of said at least two domains specifically binds to human EpCAM and comprises at least one CDR-H3 region comprising the amino acid sequence NXID antigen and a second domain binds to human CD3 antigen. The invention further provides a process for the production of the pharmaceutical composition of the invention, a method for the prevention, treatment or amelioration of a tumorous disease and the use of the disclosed bispecific single chain antibody construct and corresponding means in the prevention, treatment or amelioration of a tumorous disease.
摘要翻译：本发明提供包含双特异性单链抗体构建体的药物组合物。所述双特异性单链抗体构建体的特征在于包含至少两个结构域或由至少两个结构域组成，其中所述至少两个结构域之一特异性结合人EpCAM并且包含至少一个CDR-H3区，其包含氨基酸序列NXID抗原和第二结构域结合人CD3抗原。本发明进一步提供了制备本发明的药物组合物的方法，一种预防，治疗或改善肿瘤疾病的方法，以及所公开的双特异性单链抗体构建体的用途和相应的手段，用于预防，治疗或改善肿瘤疾病

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式